Skip to content
DataLookout
Menu

NCT05384509

(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies

StatusUnknown
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary and study completion dates pushed to Feb 28, 2025v3 Show 4 more changesShow less
    • Eligibility criteria shortened, about 10 words
    • Primary endpoints revised (8)
    • Secondary endpoints revised (8)
    • Study description expanded, about 22 words
  3. Notable Primary completion date: Nov 30, 2022 to Jul 30, 2023v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

COVID-19 N Ab trends among different subgroups (anti-cancer therapies)
Timeframe: 3 month
COVID-19 S Ab trends among different subgroups (anti-cancer therapies)
Timeframe: 3 month

Secondary (2)

COVID-19 N Ab trends among different baseline PhenoAge scores
COVID-19 S Ab trends among different baseline PhenoAge scores

Arms and interventions

Chemotherapy

Cancer Patients underwent chemotherapy

Targeted therapy

Patients underwent targeted therapy

Immunotherapy

Patients underwent immunotherapy

Disease-free

Cancer patients have been disease-free for ≥ 6 months group

Diagnostic tests: solid organ malignancies treatment

Sites

1 site in 1 country

  • TuCheng HospitalNew Taipei City, Taiwan